Abstract
Acetylcysteine has been used to treat acetaminophen overdose for nearly 50 years. While no placebo controlled trials have been conducted, the efficacy of acetylcysteine is accepted for the prevention of hepatic injury when administered early after acetaminophen overdose. Acetylcysteine can be administered as an infusion or oral solution. The duration of treatment varies from 21 to 72 hours, depending on the protocol. Acetylcysteine also prevents death when administered to patients with hepatic failure from acetaminophen.
Keywords: Acetaminophen, acetylcysteine, hepatic failure, overdose, placebo, Acetaminophen poisoning, CYP2E1, Nacetyl-p-benzoquinoneimine (NAPQI), minor metabolic pathway, therapeutic dose, hepatic injury, antidotes, glutathione, hepatic injury.
Current Pharmaceutical Biotechnology
Title:Acetylcysteine Therapy for Acetaminophen Poisoning
Volume: 13 Issue: 10
Author(s): Kennon Heard and Jody Green
Affiliation:
Keywords: Acetaminophen, acetylcysteine, hepatic failure, overdose, placebo, Acetaminophen poisoning, CYP2E1, Nacetyl-p-benzoquinoneimine (NAPQI), minor metabolic pathway, therapeutic dose, hepatic injury, antidotes, glutathione, hepatic injury.
Abstract: Acetylcysteine has been used to treat acetaminophen overdose for nearly 50 years. While no placebo controlled trials have been conducted, the efficacy of acetylcysteine is accepted for the prevention of hepatic injury when administered early after acetaminophen overdose. Acetylcysteine can be administered as an infusion or oral solution. The duration of treatment varies from 21 to 72 hours, depending on the protocol. Acetylcysteine also prevents death when administered to patients with hepatic failure from acetaminophen.
Export Options
About this article
Cite this article as:
Heard Kennon and Green Jody, Acetylcysteine Therapy for Acetaminophen Poisoning, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273146
DOI https://dx.doi.org/10.2174/138920112802273146 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Applications of Bisheterocyclic Compounds
Current Organic Synthesis Connexins in Renal Endothelial Function and Dysfunction
Cardiovascular & Hematological Disorders-Drug Targets CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists
Current Topics in Medicinal Chemistry Metabolite Identification and Profiling in Drug Design: Current Practice and Future Directions
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry Does Pharmacological Therapy Still Play a Role in Preventing Sudden Death in Surgically Treated Tetralogy of Fallot?
Mini-Reviews in Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Platelet Aggregation and Exogenous Factors From Animal Sources
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial (Thematic Issue: Stereoselective Synthesis and Applications of Compounds with N-O Bonds)
Current Organic Synthesis C. elegans as a Genetic Model System to Identify Parkinson's Disease- Associated Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Preface: (Commentary on the Special Issue on the Impact of Myogenic Tone in Health and Disease)
Current Vascular Pharmacology Editorial: Pharmacological Therapy to Prevent Sudden Cardiac Death: Indications and Limitations in the Era of Devices
Mini-Reviews in Medicinal Chemistry Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Hypertension in Pregnancy: Clinical Manifestations and Treatment
Current Hypertension Reviews Low Doses of G-CSF Prevent Cerebral Infarction and Maintain Muscle Strength in an Experimental Model of Global Ischemic Stroke
Current Pharmaceutical Biotechnology